Biocryst Pharmaceuticals Stock EBITDA

BCRX Stock

USD 7.63 0.02 0.26%

By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess BioCryst Pharmaceuticals' long-term financial health and intrinsic value.

		Last Reported	Projected for Next Year
	EBITDA	12.8 M	13.4 M

EBITDA is likely to rise to about 13.4 M in 2025.

Build AI portfolio with BioCryst Stock

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

BioCryst Pharmaceuticals Company EBITDA Analysis

BioCryst Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current BioCryst Pharmaceuticals EBITDA

12.81 M

Most of BioCryst Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioCryst Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

BioCryst EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for BioCryst Pharmaceuticals is extremely important. It helps to project a fair market value of BioCryst Stock properly, considering its historical fundamentals such as EBITDA. Since BioCryst Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioCryst Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioCryst Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Current Deferred Revenue	Property Plant Equipment	Net Receivables	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.0	0.73	-0.94	0.78	0.95	0.99	-0.09	0.67	0.93	-0.31	0.88	0.77	-0.81	0.93	0.93	0.87	-0.66	-0.17	0.16	0.94	0.95	0.94
Total Stockholder Equity	0.0		0.14	0.18	-0.19	0.06	0.01	-0.55	-0.06	-0.3	0.45	-0.08	0.17	-0.34	0.18	0.01	-0.31	0.37	-0.02	-0.39	0.22	0.16	-0.09
Net Debt	0.73	0.14		-0.84	0.27	0.9	0.7	0.21	0.95	0.71	-0.15	0.78	0.94	-0.92	0.92	0.77	0.55	-0.39	-0.14	0.24	0.61	0.61	0.76
Retained Earnings	-0.94	0.18	-0.84		-0.67	-0.96	-0.92	-0.19	-0.83	-0.97	0.41	-0.9	-0.83	0.82	-0.93	-0.91	-0.87	0.67	0.21	-0.32	-0.8	-0.82	-0.94
Accounts Payable	0.78	-0.19	0.27	-0.67		0.62	0.82	-0.24	0.28	0.77	-0.33	0.6	0.33	-0.43	0.57	0.67	0.82	-0.55	-0.31	0.06	0.78	0.82	0.75
Total Liab	0.95	0.06	0.9	-0.96	0.62		0.94	0.03	0.83	0.9	-0.24	0.88	0.9	-0.92	0.99	0.95	0.79	-0.57	-0.23	0.18	0.87	0.88	0.94
Total Current Assets	0.99	0.01	0.7	-0.92	0.82	0.94		-0.14	0.64	0.93	-0.28	0.85	0.74	-0.81	0.91	0.94	0.87	-0.66	-0.25	0.14	0.96	0.97	0.94
Short Term Debt	-0.09	-0.55	0.21	-0.19	-0.24	0.03	-0.14		0.32	0.17	-0.49	0.04	0.11	0.13	-0.03	-0.02	-0.07	-0.17	0.06	0.54	-0.37	-0.35	0.01
Short Term Investments	0.67	-0.06	0.95	-0.83	0.28	0.83	0.64	0.32		0.71	-0.18	0.75	0.84	-0.79	0.83	0.7	0.57	-0.45	-0.11	0.28	0.5	0.51	0.72
Common Stock	0.93	-0.3	0.71	-0.97	0.77	0.9	0.93	0.17	0.71		-0.4	0.87	0.75	-0.69	0.85	0.9	0.91	-0.75	-0.24	0.39	0.79	0.82	0.95
Current Deferred Revenue	-0.31	0.45	-0.15	0.41	-0.33	-0.24	-0.28	-0.49	-0.18	-0.4		-0.2	0.04	0.11	-0.17	-0.17	-0.34	0.32	-0.02	-0.13	-0.18	-0.19	-0.22
Property Plant Equipment	0.88	-0.08	0.78	-0.9	0.6	0.88	0.85	0.04	0.75	0.87	-0.2		0.81	-0.76	0.87	0.83	0.81	-0.54	-0.11	0.33	0.76	0.77	0.82
Net Receivables	0.77	0.17	0.94	-0.83	0.33	0.9	0.74	0.11	0.84	0.75	0.04	0.81		-0.88	0.92	0.84	0.6	-0.44	-0.17	0.32	0.67	0.66	0.83
Net Tangible Assets	-0.81	-0.34	-0.92	0.82	-0.43	-0.92	-0.81	0.13	-0.79	-0.69	0.11	-0.76	-0.88		-0.96	-0.83	-0.59	0.34	0.26	-0.02	-0.82	-0.8	-0.8
Long Term Debt	0.93	0.18	0.92	-0.93	0.57	0.99	0.91	-0.03	0.83	0.85	-0.17	0.87	0.92	-0.96		0.93	0.74	-0.52	-0.24	0.15	0.87	0.87	0.91
Long Term Debt Total	0.93	0.01	0.77	-0.91	0.67	0.95	0.94	-0.02	0.7	0.9	-0.17	0.83	0.84	-0.83	0.93		0.79	-0.58	-0.38	0.18	0.88	0.89	0.96
Capital Surpluse	0.87	-0.31	0.55	-0.87	0.82	0.79	0.87	-0.07	0.57	0.91	-0.34	0.81	0.6	-0.59	0.74	0.79		-0.74	-0.15	0.31	0.77	0.8	0.88
Deferred Long Term Liab	-0.66	0.37	-0.39	0.67	-0.55	-0.57	-0.66	-0.17	-0.45	-0.75	0.32	-0.54	-0.44	0.34	-0.52	-0.58	-0.74		0.09	-0.59	-0.51	-0.55	-0.64
Long Term Investments	-0.17	-0.02	-0.14	0.21	-0.31	-0.23	-0.25	0.06	-0.11	-0.24	-0.02	-0.11	-0.17	0.26	-0.24	-0.38	-0.15	0.09		-0.06	-0.25	-0.29	-0.35
Short Long Term Debt	0.16	-0.39	0.24	-0.32	0.06	0.18	0.14	0.54	0.28	0.39	-0.13	0.33	0.32	-0.02	0.15	0.18	0.31	-0.59	-0.06		-0.08	-0.04	0.25
Net Invested Capital	0.94	0.22	0.61	-0.8	0.78	0.87	0.96	-0.37	0.5	0.79	-0.18	0.76	0.67	-0.82	0.87	0.88	0.77	-0.51	-0.25	-0.08		0.99	0.86
Net Working Capital	0.95	0.16	0.61	-0.82	0.82	0.88	0.97	-0.35	0.51	0.82	-0.19	0.77	0.66	-0.8	0.87	0.89	0.8	-0.55	-0.29	-0.04	0.99		0.88
Capital Stock	0.94	-0.09	0.76	-0.94	0.75	0.94	0.94	0.01	0.72	0.95	-0.22	0.82	0.83	-0.8	0.91	0.96	0.88	-0.64	-0.35	0.25	0.86	0.88

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict BioCryst Pharmaceuticals

Ebitda Over Time

BioCryst Ebitda

Ebitda

13.45 Million

At this time, BioCryst Pharmaceuticals' EBITDA is fairly stable compared to the past year.

According to the company disclosure, BioCryst Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of 12.81 M. This is 98.54% lower than that of the Biotechnology sector and 87.21% lower than that of the Health Care industry. The ebitda for all United States stocks is 99.67% higher than that of the company.

BioCryst EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioCryst Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics of similar companies.

BioCryst Pharmaceuticals is currently under evaluation in ebitda category among its peers.

BioCryst Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, BioCryst Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to BioCryst Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

BioCryst Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in BioCryst Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioCryst Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioCryst Pharmaceuticals' value.

		Shares
Two Sigma Investments Llc	2025-06-30	4.3 M
Arrowstreet Capital Limited Partnership	2025-06-30	4.3 M
Two Sigma Advisers, Llc	2025-06-30	4.2 M
Rp Management, Llc	2025-03-31	3.8 M
Assenagon Asset Management Sa	2025-06-30	3.6 M
Nuveen, Llc	2025-06-30	3.5 M
Goldman Sachs Group Inc	2025-06-30	3.5 M
Bank Of America Corp	2025-06-30	2.8 M
Fisher Asset Management, Llc	2025-06-30	2.8 M
Blackrock Inc	2025-06-30	21.4 M
Vanguard Group Inc	2025-06-30	20.5 M

BioCryst Fundamentals

	Return On Equity	-19.25
	Return On Asset	0.0746
	Profit Margin	(0.06) %
	Operating Margin	0.18 %
	Current Valuation	2.05 B
	Shares Outstanding	209.92 M
	Shares Owned By Insiders	1.26 %
	Shares Owned By Institutions	99.41 %
	Number Of Shares Shorted	28.32 M
	Price To Earning	(7.11) X
	Price To Book	56.59 X
	Price To Sales	2.88 X
	Revenue	450.71 M
	Gross Profit	370.64 M
	EBITDA	12.81 M
	Net Income	(88.88 M)
	Cash And Equivalents	417.48 M
	Cash Per Share	2.24 X
	Total Debt	841.42 M
	Debt To Equity	2.40 %
	Current Ratio	5.19 X
	Book Value Per Share	(2.01) X
	Cash Flow From Operations	(52.02 M)
	Short Ratio	12.15 X
	Earnings Per Share	(0.18) X
	Price To Earnings To Growth	(0.28) X
	Target Price	17.2
	Number Of Employees	580
	Beta	1.13
	Market Capitalization	1.61 B
	Total Asset	490.42 M
	Retained Earnings	(1.77 B)
	Working Capital	261.58 M
	Current Asset	65.99 M
	Current Liabilities	64.45 M
	Net Asset	490.42 M

About BioCryst Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze BioCryst Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

NOAH	Noah Holdings
CIG	Companhia Energetica de
BBVA	Banco Bilbao Viscaya

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC